Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator
Authors:
- Irina V. ZabbarovaIZIrina V. Zabbarova
- Youko IkedaYIYouko Ikeda
- Pradeep TyagiPTPradeep Tyagi
- Lori A BirderLBLori A Birder
- Basu ChakrabartyBCBasu Chakrabarty
- Subashan Kpg PereraSPSubashan Kpg Perera
- Rajiv DhirRDRajiv Dhir
- Adam C. StraubAdam C. Straub
- Peter SandnerPSPeter Sandner
- Karl‐Erik AnderssonKAKarl‐Erik Andersson
- Marcus J DrakeMDMarcus J Drake
- 15 February 2022
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 256 (4) , 442-454
Abstract
Benign prostatic hyperplasia (BPH) is a feature of ageing males. Up to half demonstrate bladder outlet obstruction (BOO) with associated lower urinary tract symptoms (LUTS) including bladder overactivity. Current therapies to reduce obstruction, such as α1‐adrenoceptor antagonists and 5α‐reductase inhibitors, are not effective in all patients. The phosphodiesterase‐5 inhibitor (PDE5I) tadalafil is also approved to treat BPH and LUTS, suggesting a role for nitric oxide (NO•), soluble guanylate cyclase (sGC), and cGMP signalling pathways. However, PDE5I refractoriness can develop for reasons including nitrergic nerve damage and decreased NO• production, or inflammation‐related oxidation of the sGC haem group, normally maintained in a reduced state by the cofactor cytochrome‐b5‐reductase 3 (CYB5R3). sGC activators, such as cinaciguat (BAY 58‐2667), have been developed to enhance sGC activity in the absence of NO• or when sGC is oxidised. Accordingly, their effects on the prostate and LUT function of aged mice were evaluated. Aged mice (≥24 months) demonstrated a functional BPH/BOO phenotype, compared with adult animals (2–12 months), with low, delayed voiding responses and elevated intravesical pressures as measured by telemetric cystometry. This was consistent with outflow tract histological and molecular data that showed urethral constriction, increased prostate weight, greater collagen deposition, and cellular hyperplasia. All changes in aged animals were attenuated by daily oral treatment with cinaciguat for 2 weeks, without effect on serum testosterone levels. Cinaciguat had only transient (1 h) cardiovascular effects with oral gavage, suggesting a positive safety profile. The benefit of cinaciguat was suggested by its reversal of an overactive cystometric profile in CYB5R3 smooth muscle knockout mice that mirrors a profile of oxidative dysfunction where PDE5I may not be effective. Thus, the aged male mouse is a suitable model for BPH‐induced BOO and cinaciguat has a demonstrated ability to reduce prostate‐induced obstruction and consequent effects on bladder function. © 2021 The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01‐DK098361)
This publication has 53 references indexed in Scilit:
- The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ SystemsPLOS ONE, 2013
- Prostatic fibrosis, lower urinary tract symptoms, and BPHNature Reviews Urology, 2013
- Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladderInternational Journal of Urology, 2012
- Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfideAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative StressFrontiers in Pharmacology, 2012
- Vardenafil Decreases Bladder Afferent Nerve Activity in Unanesthetized, Decerebrate, Spinal Cord–Injured RatsEuropean Urology, 2010
- The effect of sildenafil citrate on bladder outlet obstruction: a mouse modelBJU International, 2009
- Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTSNeurourology and Urodynamics, 2007
- cGMP‐enhancing‐ and α1A/α1D‐adrenoceptor blockade‐derived inhibition of Rho‐kinase by KMUP‐1 provides optimal prostate relaxation and epithelial cell anti‐proliferation efficacyThe Prostate, 2007
- Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular RemodelingCirculation, 2006